Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $51.9052W HIGH $76.07
Volume
102.03 M
Value Traded
7.76 B
Short % Float
3.74%
+0.3%Week
+0.68%1 Month
+1.64%3 Month
+12.41%6 Month
+2.03%5 Year
+3,079.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
16.97 B
EPS (TTM)
2.43
P/E Ratio
31.54
Ent. Value
17.12 B
Total Shares
223.13 M
Float Shares
219.11 M
Insiders
1.55%
Institutions
96.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HOLX Catalyst Timeline
Dated clinical, regulatory and corporate events for Hologic, Inc.
Past FDA Catalysts and PDUFA Decisions
How HOLX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
3
Drugs Scored
-
rNPV / MCap
Hologic, Inc. faces pipeline headwinds (27/100), with 3 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every HOLX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Verstreken JanOfficer (Group President, International) | Disposition | -134,039 | $0.00 | 04/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HOLX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.5 % (-28.6 %) | 6.75 M | 100.00 K | -20% ( -25.00 K) |
HOLX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HOLX ranks across every disease it competes in
Competitive Position is a premium feature
See how HOLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHOLX News
About Hologic, Inc.
Headquarters250 CAMPUS DRIVE, MARLBOROUGH, MA, 01752
Founded1985
BIOPHARMAWATCH ELITE PLUS
Trade the next HOLX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime